**Core Concept**
Nateglinide is a rapidly acting meglitinide analog used in the management of type 2 diabetes mellitus. It works by stimulating insulin release from the pancreas through closure of ATP-sensitive potassium channels.

**Why the Correct Answer is Right**
Nateglinide acts by binding to the SUR1 (sulfonylurec receptor 1) subunit of the ATP-sensitive potassium channel in pancreatic beta cells. This binding causes a conformational change that leads to the closure of the potassium channels, depolarization of the beta cell membrane, and subsequent opening of voltage-dependent calcium channels. The influx of calcium ions triggers insulin release from the pancreas.

**Why Each Wrong Option is Incorrect**
**Option A:** Nateglinide is not a sulfonylurea, but rather a meglitinide analog. It has a different mechanism of action and is not associated with the same risks of hypoglycemia as sulfonylureas.
**Option B:** Nateglinide does not act through the inhibition of glucagon secretion. Its primary mechanism is the stimulation of insulin release.
**Option C:** Nateglinide is not a DPP-4 inhibitor, which is a class of oral hypoglycemic agents that work by inhibiting the enzyme dipeptidyl peptidase-4.

**Clinical Pearl / High-Yield Fact**
Nateglinide and other meglitinide analogs can cause hypoglycemia due to their ability to stimulate insulin release from the pancreas. This risk is particularly high when used in combination with other insulin secretagogues or in patients with impaired renal function.

**Correct Answer: C. Nateglinide is a meglitinide analog used to stimulate insulin release from the pancreas.**